Pharmaceuticals in Brief
14 June 2004 00:01 [Source: ICB Americas]
ImClone Systems Inc. and Merck KGaA report that their cancer vaccine, IMC-BEC2, failed to meet the primary end point—survival—in a Phase III clinical trial. IMC-BEC2 mimics a ganglioside expressed on the cell membrane of most small-cell lung cancer tumors. The companies have yet to determine the future of the IMC-BEC2 development program.
Jungbunzlauer is increasing the prices of citric acid anhydrous USP/FCC and trisodium citrate dehydrate USP/FCC by approximately 7 to 10 percent to customers in the US, Canada and Mexico. The increase takes effect July 15, or as contracts allow.
In Brief
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Related Articles
- 06 Dec 04 00:01 The Perils and Possibilities of the Pipeline
- 08 Nov 04 00:01 How Does Your Pipeline Grow?
- 06 Aug 04 00:00 ImClone obtains FDA approval for Erbitux production.
- 07 Jun 04 00:01 Cancer Vaccines Advance To Commercialization, But Challenges Lie Ahead in the Road to Success
- 30 Sep 02 00:00 Technology Watch: Nanotechnology Emerges in Drug Delivery
Latest News
- 23 May 13 04:43 China’s preliminary PMI for May falls to seven-month low
- 23 May 13 04:09 S Korea's S-Oil runs No 2 aromatics unit at 100% after turnaround
- 23 May 13 03:11 China’s Sinochem Fuling to start up sulphuric acid unit in Q4 2013
- 23 May 13 00:18 LNG exports can benefit US but need limits and future guidelines
- 22 May 13 23:59 Europe May ethanolamine prices move down on feedstock fall